Canada - English - Health Canada

nuron biotech b.v. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm-197 protein - suspension - 10mcg; 15mcg - meningococcal group c oligosaccharide 10mcg; corynebacterium diphtheriae crm-197 protein 15mcg - vaccines

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - neisseria meningitidis group c polysaccharide 10ug (polysaccharide antigen from strain c11, conjugated to tetanus toxoid) - suspension for injection - 10 mcg/0.5ml - active: neisseria meningitidis group c polysaccharide 10ug (polysaccharide antigen from strain c11, conjugated to tetanus toxoid) excipient: aluminium hydroxide sodium chloride tetanus toxoid water for injection - active immunisation of children from 8 weeks of age, adolescents and adults for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

Ireland - English - HPRA (Health Products Regulatory Authority)

john wyeth & brother limited - meningococcal polysaccharide group c - suspension for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - salmonella typhi vi polysaccharide, quantity: 0.025 mg - injection, solution - excipient ingredients: monobasic sodium phosphate; phenol; water for injections; sodium chloride; dibasic sodium phosphate dihydrate - for the active immunisation against typhoid fever, in subjects over 5 years of age. indications as at 9 october 2000: typhim vi is indicated for active immunisation against typhoid fever in subjects 2 years of age and over.

United States - English - NLM (National Library of Medicine)

novartis vaccines and diagnostics s.r.l. - neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen (unii: 3o44u6xyqk) (neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen - unii:3o44u6xyqk) - neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen 10 ug in 0.5 ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - neisseria meningitidis group a polysaccharide 50ug;  ; neisseria meningitidis group c polysaccharide 50ug;  ; neisseria meningitidis group w135 polysaccharide 50ug;  ; neisseria meningitidis group y polysaccharide 50ug;   - suspension for injection - 50µg/0.5ml - active: neisseria meningitidis group a polysaccharide 50ug   neisseria meningitidis group c polysaccharide 50ug   neisseria meningitidis group w135 polysaccharide 50ug   neisseria meningitidis group y polysaccharide 50ug   excipient: sucrose trometamol sodium chloride water for injection - mencevax acwy is indicated for active immunisation of adults and children over two years against meningococcal meningitis caused by group a, group c, group w-135 and group y meningococci. the vaccine may also be used for: · subjects who are close contacts of patients with disease caused by meningococci of groups a, c, w-135 and y. · travellers to countries where the disease is epidemic or highly endemic. · controlling epidemics of infection caused by group a, c, w-135, y meningococci in confined communities. mencevax acwy is not recommended for use in infants and children under two years of age, as antigenicity of the vaccine is low in this age group and antibodies persist for shorter duration.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - meningococcal vaccines group a 50 mcg / 0.5 ml; meningococcal vaccines group c 50 mcg / 0.5 ml - solution for injection - other meningococcal monovalent purified polysaccharides antigen - for the active immunization of adults and children over two years against meningococcal meningitis caused by group a, group c, group w 135 and group y meningococci.

Malta - English - Malta Medicines Authority

pfizer healthcare ireland - neisseria meningitidis polysaccharide group c 10 µg, aluminium 10 µg, corynebacterium diphtheriae crm197 carrier protein 10 µg - suspension for injection

Canada - English - Health Canada

pfizer canada ulc - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 19f; pneumococcal polysaccharide serotype 23f; corynebacterium diphtheriae crm-197 protein - suspension - 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 4.4mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 34mcg - pneumococcal polysaccharide serotype 1 2.2mcg; pneumococcal polysaccharide serotype 3 2.2mcg; pneumococcal polysaccharide serotype 4 2.2mcg; pneumococcal polysaccharide serotype 5 2.2mcg; pneumococcal polysaccharide serotype 6a 2.2mcg; pneumococcal polysaccharide serotype 6b 4.4mcg; pneumococcal polysaccharide serotype 7f 2.2mcg; pneumococcal polysaccharide serotype 9v 2.2mcg; pneumococcal polysaccharide serotype 14 2.2mcg; pneumococcal polysaccharide serotype 18c 2.2mcg; pneumococcal polysaccharide serotype 19a 2.2mcg; pneumococcal polysaccharide serotype 19f 2.2mcg; pneumococcal polysaccharide serotype 23f 2.2mcg; corynebacterium diphtheriae crm-197 protein 34mcg - vaccines

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (unii: luy6p8763w) (haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen - unii:luy6p8763w) - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen 7.5 ug in 0.5 ml - liquid pedvaxhib is indicated for routine vaccination against invasive disease caused by haemophilus influenzae type b in infants and children 2 to 71 months of age. liquid pedvaxhib will not protect against disease caused by haemophilus influenzae other than type b or against other microorganisms that cause invasive disease such as meningitis or sepsis. as with any vaccine, vaccination with liquid pedvaxhib may not result in a protective antibody response in all individuals given the vaccine. because of the potential for immune tolerance, liquid pedvaxhib is not recommended for use in infants younger than 6 weeks of age. (see precautions.) infants completing the primary two-dose regimen before 12 months of age should receive a booster dose (see dosage and administration). hypersensitivity to any component of the vaccine or the diluent. persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.